Preparation of <superscript>177</superscript>Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.
In: BioMed Research International, 2021-11-20, S. 1-12
Online
academicJournal
Zugriff:
Objective. In the recent time, endoradionuclide therapy for metastatic castration-resistant prostate carcinoma employing 177 Lu-PSMA-617 has yielded encouraging results and several clinical trials with the agent are currently ongoing. Routine preparation of 177 Lu-PSMA-617 patient doses can be made simpler and convenient, if the ingredients essential for radiolabeling are made available in a ready-to-use lyophilized form. Methods. PSMA-617 freeze-dried kit was formulated and used for the preparation of 177 Lu-PSMA-617 clinical dose with high radiochemical purity using low/medium specific activity 177 Lu. Detailed radiochemical studies were performed to determine the maximum activity and volume of 177 LuCl 3 , which can be added in the kit for the formulation of 177 Lu-PSMA-617. Studies were also performed to determine the shelf life of the kit to ensure its long-term usage. Studies were performed in buffer as well as human serum medium to determine the stability of the 177 Lu-PSMA-617 complex after storing in respective media up to 7 days postpreparation. About ten patient doses of 177 Lu-PSMA-617 were administered, and posttherapy scans were acquired. Results. The formulated freeze-dried kit of PSMA-617 could be radiolabeled with an average percentage radiochemical purity > 98.53 ± 0.38. The freeze-dried kit was found suitable for tolerating up to 0.5 mL of 177 LuCl 3 (in 0.01 N HCl) and specific activity of 555 MBq/μg (15 mCi/μg) for the preparation of the patient dose of 177 Lu-PSMA-617. The 177 Lu-PSMA-617 complex prepared using the freeze-dried kit of PSMA-617 was observed to maintain % radiochemical purity (RCP) of 96.74 ± 0.87 and 94.81 ± 2.66 , respectively, even after storing up to 7 days in buffer and human serum, respectively. 177 Lu-PSMA-617 prepared using the in-house formulated freeze-dried kit of PSMA-617 exhibited accumulation in metastatic lesions picked up in a pretherapy PET scan. Reduction in number as well as size of lesions was observed in posttherapy scans acquired after two months of administering the first therapeutic dose of 177 Lu-PSMA-617. Conclusions. The freeze-dried kit of PSMA-617 could be used for the preparation of 177 Lu-PSMA-617 with high radiochemical purity (>98%) in a reproducible manner. 177 Lu-PSMA-617 prepared using the developed kit was successfully evaluated in patients suffering from metastatic prostate cancer. [ABSTRACT FROM AUTHOR]
Copyright of BioMed Research International is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Preparation of <superscript>177</superscript>Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.
|
---|---|
Autor/in / Beteiligte Person: | Guleria, Mohini ; Amirdhanayagam, Jeyachitra ; Sarma, Haladhar D. ; Rallapeta, Ramya Priya ; Krishnamohan, V. S. ; Nimmagadda, Ajit ; Ravi, Parthasarathy ; Patri, Sailaja ; Kalawat, Tekchand ; Das, Tapas |
Link: | |
Zeitschrift: | BioMed Research International, 2021-11-20, S. 1-12 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 2314-6133 (print) |
DOI: | 10.1155/2021/1555712 |
Schlagwort: |
|
Sonstiges: |
|